Found: 13
Select item for more details and to access through your institution.
OAB-003: CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S2, doi. 10.1016/S2152-2650(21)02077-2
- By:
- Publication type:
- Article
Patient Perception of Being Involved in a Clinical Trial for Multiple Myeloma Ceri Bygrave, Tanya Burton*, Patricia Carter, Sarah Richard, Eric Low, Charlotte Bloodworth.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e156, doi. 10.1016/j.clml.2017.03.283
- By:
- Publication type:
- Article
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 2, p. 1328, doi. 10.1007/s12325-020-01601-w
- By:
- Publication type:
- Article
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00717-2
- By:
- Publication type:
- Article
Challenges in designing and running smouldering myeloma interventional clinical trials.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 5, p. 1811, doi. 10.1111/bjh.19286
- By:
- Publication type:
- Article
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 4, p. 682, doi. 10.1111/bjh.18703
- By:
- Publication type:
- Article
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 4, p. 750, doi. 10.1111/bjh.17377
- By:
- Publication type:
- Article
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 551, doi. 10.1111/bjh.16793
- By:
- Publication type:
- Article
COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 1, p. e14, doi. 10.1111/bjh.17168
- By:
- Publication type:
- Article
Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 2, p. 231, doi. 10.1111/bjh.16665
- By:
- Publication type:
- Article
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapy.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e83, doi. 10.1111/bjh.16874
- By:
- Publication type:
- Article
Risk of relapse of multiple myeloma following kidney transplantation.
- Published in:
- Clinical Kidney Journal, 2019, v. 12, n. 2, p. 216, doi. 10.1093/ckj/sfy137
- By:
- Publication type:
- Article